肝病用药剂量指南。 - Suppr

Suppr

超能文献

Guide to drug dosage in hepatic disease.

作者信息

Bass N M, Williams R L

机构信息

Department of Medicine, University of California, San Francisco.

出版信息

Clin Pharmacokinet. 1988 Dec;15(6):396-420. doi: 10.2165/00003088-198815060-00004.

DOI:10.2165/00003088-198815060-00004

PMID:3072141

Abstract

摘要

相似文献

Guide to drug dosage in hepatic disease.肝病用药剂量指南。

Clin Pharmacokinet. 1988 Dec;15(6):396-420. doi: 10.2165/00003088-198815060-00004.

Hepatic clearance measurements and pharmacokinetics.肝脏清除率测定与药代动力学。

Pharmacology. 1979;19(3):105-10. doi: 10.1159/000137296.

Is drug administration in hepatic disease really so complicated?肝脏疾病中的药物给药真的如此复杂吗？

N Engl J Med. 1984 May 17;310(20):1331-2. doi: 10.1056/nejm198405173102019.

Drug pharmacokinetics in cardiac and hepatic disease.

Annu Rev Pharmacol Toxicol. 1980;20:389-413. doi: 10.1146/annurev.pa.20.040180.002133.

[Dosage of drugs with regard to their distribution volume and biological half-life].

Tidsskr Nor Laegeforen. 1974 Jun 30;94(18):1201-2.

Clinical pharmacokinetics.

Annu Rev Pharmacol Toxicol. 1979;19:105-27. doi: 10.1146/annurev.pa.19.040179.000541.

[Principles and practical advice for drug dosages in liver diseases. I].[肝病药物剂量的原则与实用建议。I]

Cas Lek Cesk. 1984 Apr 6;123(14):416-20.

[Metabolism of drugs in the liver and disease].[肝脏中的药物代谢与疾病]

Ugeskr Laeger. 1988 Jan 25;150(4):204-9.

Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.评估 FDA 批准产品标签中肝损伤剂量建议。

J Clin Pharmacol. 2013 Sep;53(9):962-6. doi: 10.1002/jcph.128. Epub 2013 Jul 7.

[Effects of liver disease on drug pharmacokinetics].[肝脏疾病对药物药代动力学的影响]

Sheng Li Ke Xue Jin Zhan. 1983 Jul;14(3):238-42.

引用本文的文献

Camel urine as a potential source of bioactive molecules showing their efficacy against pathogens: A systematic review.骆驼尿液作为生物活性分子的潜在来源及其对病原体的功效：一项系统综述。

Saudi J Biol Sci. 2024 May;31(5):103966. doi: 10.1016/j.sjbs.2024.103966. Epub 2024 Feb 25.

A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.基于Child-Pugh分类的肝硬化患者药物暴露预测模型

Clin Pharmacokinet. 2015 Dec;54(12):1245-58. doi: 10.1007/s40262-015-0288-9.

Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.临床综述：急性肾损伤中的药物代谢与非肾清除率

Crit Care. 2008;12(6):235. doi: 10.1186/cc7093. Epub 2008 Nov 12.

Dose adaptation of antineoplastic drugs in patients with liver disease.肝病患者抗肿瘤药物的剂量调整

Drug Saf. 2006;29(6):509-22. doi: 10.2165/00002018-200629060-00004.

Effects of liver disease on pharmacokinetics. An update.肝脏疾病对药代动力学的影响。最新进展。

Clin Pharmacokinet. 1999 Nov;37(5):399-431. doi: 10.2165/00003088-199937050-00004.

Role of viral infections in the induction of adverse drug reactions.

Drug Saf. 1997 Jan;16(1):1-8. doi: 10.2165/00002018-199716010-00001.

Clinical pharmacokinetics of newer antibacterial agents in liver disease.新型抗菌药物在肝病中的临床药代动力学

Clin Pharmacokinet. 1993 Jan;24(1):46-58. doi: 10.2165/00003088-199324010-00004.

Drug-induced hepatic disorders. Incidence, management and avoidance.药物性肝病。发病率、管理与预防

Drug Saf. 1993 Dec;9(6):441-9. doi: 10.2165/00002018-199309060-00007.

Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction.新型抗高血压药物萘哌地尔在肝功能不全患者中的药代动力学

Postgrad Med J. 1994 May;70(823):363-6. doi: 10.1136/pgmj.70.823.363.

Assessment of liver metabolic function. Clinical implications.肝脏代谢功能评估。临床意义。

Clin Pharmacokinet. 1994 Sep;27(3):216-48. doi: 10.2165/00003088-199427030-00005.

本文引用的文献

Dangers of prolonged anticoagulant therapy in hepatic disease. Diathesis and intercurrent acute hepatitis.

J Am Med Assoc. 1960 Jan 16;172:223-6. doi: 10.1001/jama.1960.03020030017004.

THE METABOLISM OF TRITIATED DIGOXIN IN CIRRHOTIC PATIENTS.肝硬化患者体内氚标记地高辛的代谢

Gastroenterology. 1964 Nov;47:517-24.

DIPHENYLHYDANTOIN AND PHENOBARBITAL TOXICITY. THE ROLE OF LIVER DISEASE.二苯乙内酰脲和苯巴比妥中毒。肝脏疾病的作用。

Arch Neurol. 1964 Dec;11:649-56. doi: 10.1001/archneur.1964.00460240081011.

DISAPPEARANCE RATE OF TOLBUTAMIDE IN NORMAL SUBJECTS AND IN DIABETES MELLITUS, LIVER CIRRHOSIS, AND RENAL DISEASE.甲苯磺丁脲在正常受试者以及糖尿病、肝硬化和肾脏疾病患者中的消失率

Diabetes. 1963 Sep-Oct;12:414-9. doi: 10.2337/diab.12.5.414.

Cimetidine clearance and bioavailability in hepatic cirrhosis.西咪替丁在肝硬化中的清除率和生物利用度。

Clin Pharmacol Ther. 1981 Feb;29(2):191-7. doi: 10.1038/clpt.1981.30.

Naproxen disposition in hepatic and biliary disorders.萘普生在肝脏和胆道疾病中的处置情况。

Int J Clin Pharmacol Ther Toxicol. 1980 Jun;18(6):242-6.

Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt.

Clin Pharmacol Ther. 1980 Sep;28(3):417-24. doi: 10.1038/clpt.1980.182.

Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics.吸烟和慢性乙型肝炎对利多卡因和吲哚菁绿动力学的影响。

Clin Pharmacol Ther. 1980 Aug;28(2):208-15. doi: 10.1038/clpt.1980.152.

Pharmacokinetics of phenylbutazone in chronic liver disease.保泰松在慢性肝病中的药代动力学

Indian J Med Res. 1980 Feb;71:316-21.

The influence of ascites on the pharmacokinetics of amikacin.腹水对阿米卡星药代动力学的影响。

Int J Clin Pharmacol Ther Toxicol. 1980;18(2):57-61.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验